Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive Versant's backing in ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound ... high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main ...

Eli Lilly is a top producer of insulin and antibiotics, and a growing force in weight loss drugs and treatments for Alzheimer’s. The company is also known for drugs to treat diabetes (Trulicity ...